Axogen, Inc.
A maker of surgical products that repair damaged peripheral nerves, Axogen's lineup includes the Avance Nerve Graft (processed human nerve tissue) and the Axoguard line of porcine-based connectors, protectors, and caps used by surgeons to restore feeling and movement. The business grew out of technology licensed from the University of Florida and took its current form after a 2011 merger, with the FDA approving Avance as a licensed biologic in 2025. A neat quirk: before Avance, the standard repair often meant cutting a healthy nerve from elsewhere in the patient's own body, so the fix created a new injury.
Granted 110.3K · Sold 39.3K
Granted 11.9K · Sold 25.0K
Granted 225.2K · Sold 45.6K
Granted 300.0K
Granted 82.0K · Bought 10.0K · Sold 54.4K
Sold 3.9K
Granted 22.6K · Sold 4.1K
Granted 75.7K · Sold 12.2K
Sold 12.5K
Granted 89.2K · Sold 30.3K
Granted 150.0K · Sold 86.5K
Granted 27.9K · Sold 6.9K
Granted 92.5K · Sold 22.5K
Granted 24.6K · Sold 42.3K
Granted 36.7K · Sold 4.1K
Granted 134.8K · Sold 136.5K
Granted 44.3K · Sold 21.4K
Granted 86.3K · Bought 2.5K · Sold 74.6K
Granted 81.2K · Sold 67.1K
Granted 68.2K · Sold 60.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Zaderej Karen L.CEO, Director · 6 transactions | +6.6% | 1.14Mas of Mar 2024 | 110.3K | — | 39.3K |
| Freitag Gregory GeneDirector · 2 transactions | -4.4% | 283.5Kas of Jun 2024 | 11.9K | — | 25.0K |
| DeVinney Erick WayneChief Innovation Officer · 28 transactions | +130% | 262.8K | 225.2K | — | 45.6K |
| Naor NirCFO · 2 transactions | — | 260.9Kas of Jan 2025 | 300.0K | — | — |
| Wendell Amy McBrideDirector · 14 transactions | +53.5% | 108.0K | 82.0K | 10.0K | 54.4K |
| Quackenbush DorisSales VP · 1 transaction | — | 96.3K | — | — | 3.9K |
| Neels Guido JDirector · 3 transactions | +27.1% | 86.7Kas of Jun 2025 | 22.6K | — | 4.1K |
| Kemp JensChief Marketing Officer · 9 transactions | — | 72.5K | 75.7K | — | 12.2K |
| Mariani Peter JEVP & Chief Financial Officer · 4 transactions | -9.8% | 71.6Kas of Dec 2023 | — | — | 12.5K |
| Hartley Lindsey MarieCFO · 18 transactions | — | 65.1K | 89.2K | — | 30.3K |
| Dale Michael DChief Executive Officer · 3 transactions | — | 63.5K | 150.0K | — | 86.5K |
| Scopelianos AngeloChief R&D Officer · 7 transactions | +52.7% | 58.6Kas of Mar 2024 | 27.9K | — | 6.9K |
| Began Marc AEVP & General Counsel · 11 transactions | — | 54.6K | 92.5K | — | 22.5K |
| Donovan Michael PatrickVP Operations · 8 transactions | -26.1% | 54.3Kas of Mar 2024 | 24.6K | — | 42.3K |
| Levine Alan MDirector · 4 transactions | +178.7% | 50.9K | 36.7K | — | 4.1K |
| Burke William P. Mr.Director · 24 transactions | — | 38.7K | 134.8K | — | 136.5K |
| Thomas PaulDirector · 5 transactions | +241.2% | 32.4K | 44.3K | — | 21.4K |
| Martinez Maria D.Chief Human Resources Officer · 1 transaction | -4.4% | 30.5Kas of Oct 2023 | — | — | — |
| Tyndall Joseph A.Director · 15 transactions | — | 14.2K | 86.3K | 2.5K | 74.6K |
| Weiler Kathy JohnsonDirector · 10 transactions | — | 14.2K | 81.2K | — | 67.1K |
| Johnson JohnDirector · 12 transactions | +119.1% | 14.2K | 68.2K | — | 60.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -737.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.